Arvinas, Inc. (ARVN)
| Market Cap | 600.25M +1.2% |
| Revenue (ttm) | 316.70M -15.0% |
| Net Income | 9.30M |
| EPS | 0.13 |
| Shares Out | 65.39M |
| PE Ratio | 68.67 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 600,337 |
| Open | 9.17 |
| Previous Close | 9.24 |
| Day's Range | 9.03 - 9.24 |
| 52-Week Range | 6.97 - 14.51 |
| Beta | 1.74 |
| Analysts | Buy |
| Price Target | 13.93 (+51.74%) |
| Earnings Date | Aug 4, 2026 |
About ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, suc... [Read more]
Financial Performance
In 2025, Arvinas's revenue was $262.60 million, a decrease of -0.30% compared to the previous year's $263.40 million. Losses were -$80.80 million, -59.38% less than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for ARVN stock is "Buy." The 12-month stock price target is $13.93, which is an increase of 51.74% from the latest price.
News
Arvinas price target lowered to $10 from $11 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $10 from $11 and keeps an Equal Weight rating on the shares.
Arvinas price target lowered to $14 from $19 at Evercore ISI
Evercore ISI lowered the firm’s price target on Arvinas (ARVN) to $14 from $19 and keeps an Outperform rating on the shares.
Arvinas price target lowered to $21 from $24 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Arvinas (ARVN) to $21 from $24 and keeps a Buy rating on the shares.
Arvinas price target raised to $12 from $11 at Wedbush
Wedbush analyst Robert Driscoll raised the firm’s price target on Arvinas (ARVN) to $12 from $11 and keeps a Neutral rating on the shares. The firm notes the company reported…
Wells downgrades Arvinas to Equal Weight, sees catalysts coming in 2027
As previously reported, Wells Fargo downgraded Arvinas (ARVN) to Equal Weight from Overweight with a price target of $11, down from $15. While “intrigued” by the company’s early-stage pipeline, the…
Arvinas downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo analyst Derek Archila downgraded Arvinas (ARVN) to Equal Weight from Overweight.
Arvinas reports Q2 EPS $2.58, consensus (28c)
Reports Q2 revenue $249.7M, consensus $60.69M. The revenue increase of $227.3M was primarily due to $112.6M of revenue from the original vepdegestrant collaboration agreement with Pfizer driven by the...
Arvinas Earnings Call Transcript: Q2 2026
Q2 2026 saw FDA approval and out-licensing of VEPPANU, driving $249.7M in revenue and a strong cash position. Focus shifted to phase I oncology and neurology assets, with key data readouts expected in 2026–2027 and a cash runway into 2028.
Arvinas Earnings release: Q2 2026
Arvinas released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Arvinas Quarterly report: Q2 2026
Arvinas has published its Q2 2026 quarterly earnings report on August 4, 2026.
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates s...
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that mana...
Arvinas Transcript: AGM 2026
The meeting was held virtually, with a quorum established and all agenda items—including director elections, executive compensation, and auditor ratification—approved by shareholders. No questions were submitted, and risks related to forward-looking statements were noted.
Arvinas Transcript: Jefferies Global Healthcare Conference 2026
The event highlighted the first approval of a PROTAC degrader, a robust pipeline with multiple phase I programs, and a disciplined strategy prioritizing internal development for high-impact indications like PSP and SBMA. Key milestones include upcoming clinical data for LRRK2, SBMA, and oncology programs.
Arvinas to Present at Jefferies Global Healthcare Conference
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou...
Arvinas Employees Give Back During Company-wide Impact Day
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, to...
Arvinas price target raised to $16 from $14 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Arvinas (ARVN) to $16 from $14 and keeps a Neutral rating on the shares. Arvinas and Pfizer (PFE) entered into…
Arvinas price target raised to $18 from $16 at BTIG
BTIG raised the firm’s price target on Arvinas (ARVN) to $18 from $16 and keeps a Buy rating on the shares. Along with its Q1 results, the company announced it…
Arvinas price target raised to $20 from $18 at Barclays
Barclays raised the firm’s price target on Arvinas (ARVN) to $20 from $18 and keeps an Overweight rating on the shares post the Q1 report. The firm says the company’s…
H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’
After Rigel Pharmaceuticals (RIGL) announced it has entered into an exclusive global licensing agreement with Pfizer (PFE) and Arvinas (ARVN) for Veppanu for the treatment of ER+/HER2-, ESR1-mutated a...
Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu
Arvinas (ARVN) and Pfizer (PFE) have entered into a license agreement with Rigel Pharmaceuticals (RIGL) for the exclusive global development, manufacturing, and commercialization rights for Veppanu. V...
Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer
Rigel Pharmaceuticals (RIGL) announced that it has entered into an exclusive, global license agreement with Arvinas (ARVN) and Pfizer (PFE), subject to regulatory clearance, to develop, manufacture an...
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product on the market.
Arvinas Earnings Call Transcript: Q1 2026
FDA approval and out-licensing of VEPPANU mark a major milestone, enabling focus on a robust pipeline in oncology, neurology, and neuromuscular diseases. Strong cost controls and a $614.9M cash position support operations into 2028.
Arvinas Quarterly report: Q1 2026
Arvinas has published its Q1 2026 quarterly earnings report on May 12, 2026.